Belgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis.
GSK has stopped developing camlipixant for refractory chronic cough after mixed Phase 3 results, adding another setback to a P2X3 drug class that has repeatedly struggled to turn biological promise into convincing clinical benefits.
On 13–14 October 2026, BIOTECH SUMMIT AUSTRIA brings Europe’s biotech community to Innsbruck for high-level keynotes, policy insights, partnering and networking
in a landmark Alpine setting.
https://european-biotechnology.com/wp-content/uploads/2026/06/Headerbild-Vorbericht.jpg9002300Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2026-07-20 08:00:022026-06-29 08:40:59Stepping up in Innsbruck
UK biotech companies raised £2.11 billion in equity financing in the second quarter of 2026, as a record round for Isomorphic Labs pushed venture investment to its highest level in five years.
https://european-biotechnology.com/wp-content/uploads/2026/07/nick-fewings-Ej-5j80voU0-unsplash-scaled.jpg17072560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-20 01:01:582026-07-17 14:39:05Isomorphic megadeal lifts UK biotech funding to five-year high
French techbio Orakl Oncology has secured exclusive rights to four undisclosed oncology assets from Sanofi, giving the startup an opportunity to test whether its combination of patient-derived tumour models and artificial intelligence can improve drug development decisions.
https://european-biotechnology.com/wp-content/uploads/2026/07/immo-wegmann-LtqT12DQpt4-unsplash-scaled.jpg17022560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-17 11:33:112026-07-17 11:33:11Orakl takes on four Sanofi cancer assets
UK biotech Mission Therapeutics has sold its Phase 2-ready acute kidney injury drug MTX652 to Australia’s Dimerix in a deal worth up to $292 million (€254.7 million), freeing Mission to concentrate resources on its central nervous system (CNS) pipeline.
https://european-biotechnology.com/wp-content/uploads/2026/07/paul-skorupskas-7KLa-xLbSXA-unsplash-scaled.jpg17072560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-17 10:56:222026-07-17 10:56:22Mission Therapeutics refocuses on CNS and sells $292M kidney drug to Dimerix
Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British roots into one of the sector’s largest pharmaceutical takeovers.
https://european-biotechnology.com/wp-content/uploads/2026/07/allison-saeng-KDHe2zduHso-unsplash-scaled.jpg19202560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-17 10:10:512026-07-17 10:11:48Lilly buys Europe-rooted AtaiBeckley for up to $3.8B
Sanofi has sued Pfizer and Moderna, alleging that their COVID-19 and respiratory syncytial virus (RSV) vaccines infringe patents covering the delivery of messenger RNA using lipid nanoparticles it acquired through the acquisition of Translate Bio in 2021.
Professor Andreas Pahl took over as Chief Executive Officer of Simris Biologics GmbH in mid-July. The subsidiary of Swedish Simris Group based in Berlin, develops next-generation antibody-drug conjugate (ADC) payloads based on nature-derived technologies.
https://european-biotechnology.com/wp-content/uploads/2026/07/tk.de_Andreas_Pahl_Heidelberg_Pharma.jpg300267Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2026-07-15 13:30:182026-07-15 13:18:07ADC expert appointed as CEO
AstraZeneca has agreed to pay up to $1.5bn for global rights to Zegfrovy, an EGFR-targeted lung cancer drug developed by Dizal Pharmaceutical – the Chinese biotech it helped create nearly a decade ago.
https://european-biotechnology.com/wp-content/uploads/2026/07/anna-mateeva-y5DmtzKq2M8-unsplash-scaled.jpg19202560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-15 09:21:122026-07-15 09:21:12AstraZeneca reunites with Dizal in $1.5bn lung cancer deal
Sightera raises €3M to advance AI-generated molecular glues
Latest NewsBelgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis.
GSK setback deepens P2X3 cough drug doubts
Latest NewsGSK has stopped developing camlipixant for refractory chronic cough after mixed Phase 3 results, adding another setback to a P2X3 drug class that has repeatedly struggled to turn biological promise into convincing clinical benefits.
Stepping up in Innsbruck
AssociationsOn 13–14 October 2026, BIOTECH SUMMIT AUSTRIA brings Europe’s biotech community to Innsbruck for high-level keynotes, policy insights, partnering and networking
in a landmark Alpine setting.
Isomorphic megadeal lifts UK biotech funding to five-year high
Latest NewsUK biotech companies raised £2.11 billion in equity financing in the second quarter of 2026, as a record round for Isomorphic Labs pushed venture investment to its highest level in five years.
Orakl takes on four Sanofi cancer assets
Latest NewsFrench techbio Orakl Oncology has secured exclusive rights to four undisclosed oncology assets from Sanofi, giving the startup an opportunity to test whether its combination of patient-derived tumour models and artificial intelligence can improve drug development decisions.
Mission Therapeutics refocuses on CNS and sells $292M kidney drug to Dimerix
Latest NewsUK biotech Mission Therapeutics has sold its Phase 2-ready acute kidney injury drug MTX652 to Australia’s Dimerix in a deal worth up to $292 million (€254.7 million), freeing Mission to concentrate resources on its central nervous system (CNS) pipeline.
Lilly buys Europe-rooted AtaiBeckley for up to $3.8B
Latest NewsEli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British roots into one of the sector’s largest pharmaceutical takeovers.
Sanofi joins the mRNA vaccine patent wars
Latest NewsSanofi has sued Pfizer and Moderna, alleging that their COVID-19 and respiratory syncytial virus (RSV) vaccines infringe patents covering the delivery of messenger RNA using lipid nanoparticles it acquired through the acquisition of Translate Bio in 2021.
ADC expert appointed as CEO
AppointmentsProfessor Andreas Pahl took over as Chief Executive Officer of Simris Biologics GmbH in mid-July. The subsidiary of Swedish Simris Group based in Berlin, develops next-generation antibody-drug conjugate (ADC) payloads based on nature-derived technologies.
AstraZeneca reunites with Dizal in $1.5bn lung cancer deal
Latest NewsAstraZeneca has agreed to pay up to $1.5bn for global rights to Zegfrovy, an EGFR-targeted lung cancer drug developed by Dizal Pharmaceutical – the Chinese biotech it helped create nearly a decade ago.